共 50 条
- [43] Population pharmacokinetic (PK)-pharmacodynamic (PD) meta-analysis of sunitinib malate (SU11248) efficacy and tolerability endpoints in gastrointestinal stromal tumor (GIST), metastatic renal cell carcinoma (MRCC) and solid tumor patients. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9075S - 9076S
- [49] Continuous daily dosing (CDD) study of sunitinib malate (SU) in patients (pts) with advanced GIST compares favorably with intermittent dosing EJC SUPPLEMENTS, 2007, 5 (04): : 402 - 402